FDA Clears Phase 1 Clinical Trial of ATA2271 for Treatment of Advanced Mesothelioma
September 15th 2020The FDA accepted an investigational new drug application providing clearance to begin an open-label, single-arm phase 1 clinical trial of ATA2271, a next-generation mesothelin targeting CAR T-cell therapy.
Phase 2 CheckMate 650 Trial Shows Promise for Nivolumab, Ipilimumab Combo in mCRPC
September 14th 2020Researchers indicated that these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.
Thomas Slavin, MD, FACMG, DABCC, Discusses the Use of the myChoice CDx for Ovarian Cancer
September 11th 2020New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.
sBLA Submitted Seeking Approval of Daratumumab, Hyaluronidase-fihj Combo for AL Amyloidosis
September 11th 2020The supplemental biologics license application is seeking approval for the treatment of patients with light chain amyloidosis and is supported by results observed in the phase 3 ADROMEDA study.
Capmatinib Shows Antitumor Activity in Advanced NSCLC with a MET exon 14 Skipping Mutation
September 10th 2020Capmatinib (Tabrecta) demonstrated substantial antitumor activity in patients with advanced non-small cell lung cancer with a MET exon 14 skipping mutation, especially in those not treated previously.
Phase 3 TOURMALINE-MM2 Fails to Meet Primary End Point of PFS
September 10th 2020The study is evaluating the addition of ixazomib (Ninlaro) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Phase 2 CLOVER-1 Study Shows Promise for Patients with Triple Class Refractory Multiple Myeloma
September 9th 2020A clinically meaningful 40% overall response rate was seen in a subset of patients with triple class refractory multiple myeloma who received CLR 131 at a total administered dose of 60 mCi or greater.
FDA Issues Alert for Atezolizumab, Paclitaxel Combination in Patients with TNBC
September 9th 2020The agency indicated that the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated, inoperable, locally advanced, or metastatic triple negative breast cancer was not effective in treating the disease.
FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLC
September 8th 2020The approval was based on results from the phase 1/2 ARROW clinical trial, which demonstrated efficacy for pralsetinib in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.
The Role of Patient-Centered Medical Homes and Changes in Care Among Low-Income Patients
September 4th 2020The authors suggested that the “results of the current study have provided valuable insight into chronic medication adherence and health care use in a low-income population of patients with and without cancer.”